SNY - Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories | Benzinga

September, 20 2023 01:56 PM Sanofi

Benzinga

Elon Musk's brain-computer interface company, Neuralink, has initiated recruiting its first test subjects for human trials aimed at assisting individuals with paralysis in controlling devices.
Neuralink announced that it has obtained approval from an independent institutional review board and the initial hospital site, enabling the commencement of recruitment for its first-in-human clinical trial known as "The PRIME Study" (Precise Robotically Implanted Brain-Computer Interface).

The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for adults and children ≥30 kg.
ARS Pharma's Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi SA's (NASDAQ: SNY) Auvi-Q filled with epinephrine.

Eli Lilly And Co (NYSE: LLY) has taken legal action against ten entities in the U.S., including medical spas, wellness centers, and compounding pharmacies, alleging that they have been selling unauthorized, less expensive versions of its diabetes drug, Mounjaro (tirzepatide).
Eli Lilly has lodged four distinct lawsuits in federal courts in Florida and Texas. These lawsuits aim to obtain court orders that prevent Better Life Pharmacy, ReviveRX, Rx Compound Store, and Wells Pharmacy Network from marketing tirzepatide and seek unspecified monetary damages.

General Mills Inc (NYSE: GIS) reported first-quarter FY24 sales growth of 4% year-on-year to $4.90 billion, beating the analyst consensus of $4.88 billion. Adjusted EPS of $1.09 topped the consensus of $1.08.
Outlook: General Mills reaffirmed its FY24 organic sales growth outlook of 3% - 4%.

Boeing Co (NYSE: BA) has anticipated that China will require 8,560 new commercial airplanes through 2042.
The company arrived at the figure considering the possible economic growth well above the global average and increasing demand for domestic air travel.